Institute for Ageing and Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
Nuclear Medicine Department, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, UK.
Mov Disord. 2018 Jul;33(7):1130-1138. doi: 10.1002/mds.27403. Epub 2018 Apr 19.
Amyloid deposition is common in dementia with Lewy bodies, but its pathophysiological significance is unclear.
The objective of this study was to investigate the relationship between amyloid deposition and clinical profile, gray matter volume, and brain perfusion in dementia with Lewy bodies.
Dementia with Lewy bodies (n = 37), Alzheimer's disease (n = 20), and controls (n = 20) underwent a thorough clinical assessment, 3T MRI, and early- and late-phase F-Florbetapir PET-CT to assess cortical perfusion and amyloid deposition, respectively. Amyloid scans were visually categorized as positive or negative. Image analysis was carried out using statistical parametric mapping (SPM) 8.
There were no significant differences between amyloid-positive and amyloid-negative dementia with Lewy bodies cases in age (P = .78), overall cognitive impairment (P = .83), level of functional impairment (P = .80), or any other clinical or cognitive scale. There were also no significant differences in hippocampal or gray matter volumes. However, amyloid-positive dementia with Lewy bodies cases had lower medial temporal lobe perfusion (P = .03) than amyloid-negative cases, although a combination of medial temporal lobe perfusion, hippocampal volume, and cognitive measures was unable to accurately predict amyloid status in dementia with Lewy bodies.
Amyloid deposition was not associated with differences in clinical or neuropsychological profiles in dementia with Lewy bodies, but was associated with imaging evidence of medial temporal lobe dysfunction. The presence of amyloid in dementia with Lewy bodies cannot be identified on the basis of clinical and other imaging features and will require direct assessment via PET imaging or CSF. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
淀粉样蛋白沉积在路易体痴呆中很常见,但它的病理生理意义尚不清楚。
本研究旨在探讨路易体痴呆患者中淀粉样蛋白沉积与临床特征、灰质体积和脑灌注之间的关系。
对 37 例路易体痴呆患者、20 例阿尔茨海默病患者和 20 例对照组进行了详细的临床评估、3T MRI 检查和早期和晚期 F-Florbetapir PET-CT 检查,以评估皮质灌注和淀粉样蛋白沉积情况。淀粉样蛋白扫描结果通过视觉分类为阳性或阴性。采用统计参数映射(SPM)8 进行图像分析。
在年龄(P = .78)、总体认知障碍(P = .83)、功能障碍程度(P = .80)或任何其他临床或认知量表方面,淀粉样蛋白阳性和阴性的路易体痴呆患者之间均无显著差异。海马体或灰质体积也没有显著差异。然而,淀粉样蛋白阳性的路易体痴呆患者的内侧颞叶灌注较低(P = .03),尽管内侧颞叶灌注、海马体体积和认知测量的组合仍无法准确预测路易体痴呆患者的淀粉样蛋白状态。
淀粉样蛋白沉积与路易体痴呆患者的临床或神经心理学特征无差异相关,但与内侧颞叶功能障碍的影像学证据相关。路易体痴呆患者的淀粉样蛋白沉积不能基于临床和其他影像学特征来识别,需要通过 PET 成像或 CSF 直接评估。© 2018 作者。运动障碍由 Wiley 期刊出版公司代表国际帕金森病和运动障碍协会出版。